Promises Without Evidence
Responses commit to new SOPs and retraining while the underlying validation gaps stay untouched. The inspector returns, asks for the qualification records, and the finding repeats.

An FDA 483, a warning letter, or a failed customer audit puts your operation on a clock. Responses written under pressure promise fixes; follow-up inspections check whether the evidence exists. We triage every observation to its root cause, sequence corrective actions by risk, and build the validation evidence your response commits to — so the next inspection finds closures, not repeats.
Observations carry response deadlines. Warning letters escalate. And every commitment you make in writing becomes the checklist for the follow-up inspection.
We've seen these patterns from the other side of the table.
Responses commit to new SOPs and retraining while the underlying validation gaps stay untouched. The inspector returns, asks for the qualification records, and the finding repeats.
Deviations close with ‘retrained operator’ while the unvalidated process keeps producing the same deviation. Repeat observations escalate faster than first ones.
Twenty open actions, no sequencing. High-risk gaps wait behind low-risk paperwork while the re-inspection date approaches.
Actions are ‘done’ but the records are scattered, unsigned, or missing. A closure without evidence is a finding waiting for its second inspection.
Four phases, sequenced by risk and deadline — built around what the follow-up inspection will actually check.
Every 483 observation, warning-letter item, or audit finding is mapped to its root cause and risk-ranked. You get a register that separates ‘fix this week’ from ‘fix this quarter’ — and says why.
Each root cause gets a corrective-action plan with owner, evidence deliverable, and deadline. The plan becomes the backbone of your written response to the agency.
We execute the missing validation: qualification protocols, system validation, data-integrity controls, documentation — the records your response promised.
Before the follow-up inspection, we verify every committed action the way an inspector would: evidence first, assertions never. Gaps found here are cheap; gaps found by FDA are not.
Cannabis is our home base — the method was built there first. The same evidence discipline serves each industry below, mapped to its own regulations.
Preventive controls, supplier verification, environmental monitoring, and traceability under 21 CFR Part 117 and FSMA.
Component qualification, master manufacturing records, and laboratory controls under 21 CFR Part 111.
Safety substantiation, GMP records, and adverse-event readiness under MoCRA.
Preventive controls for animal food, supplier programs, and sanitation under 21 CFR Part 507.
Immediately. Triage begins with your 483 and existing records — no waiting for a formal kickoff. The 15-business-day response window drives the schedule, and we build the plan to meet it.
We build the technical backbone: root-cause analysis, corrective-action commitments, and the evidence timeline. Your quality leadership signs the letter — we make sure every sentence in it is defensible.
Then the remediation is a data-integrity program: audit-trail controls, access remediation, retrospective review where warranted, and ALCOA+ practices that change behavior. Our data-integrity practice covers the full method.
Yes — that's the normal model. Your team owns the quality system; we bring remediation bandwidth and outside-in discipline. We leave your people stronger than we found them, with templates and routines that persist.
Every remediation ends with preventive controls: periodic review schedules, change-control discipline, and monitoring routines tied to the root causes we found. Closure without prevention is just a pause.
Start with a confidential conversation about your observations — what's cited, what's due, and what the path to closure looks like.